scholarly journals Pharmacogenomics and Efficacy of Risperidone Long-Term Treatment in Thai Autistic Children and Adolescents

2017 ◽  
Vol 121 (4) ◽  
pp. 316-324 ◽  
Author(s):  
Nopphadol Nuntamool ◽  
Nattawat Ngamsamut ◽  
Natchaya Vanwong ◽  
Apichaya Puangpetch ◽  
Monpat Chamnanphon ◽  
...  
Keyword(s):  
Children And Adolescents ◽  
Term Treatment ◽  
Autistic Children ◽  
Long Term Treatment

Long-term treatment of obese children and adolescents using a telemedicine support programme

2008 ◽  
Vol 14 (1) ◽  
pp. 13-16 ◽  
Author(s):  
Ralf Schiel ◽  
Wadim Beltschikow ◽  
Sandra Radón ◽  
Guido Kramer ◽  
Ralf Schmiedel ◽  
...  
Keyword(s):  
Children And Adolescents ◽  
Term Treatment ◽  
Obese Children ◽  
Support Programme ◽  
Long Term Treatment

Graves' disease in children and adolescents: Response to long-term treatment

2005 ◽  
Vol 94 (11) ◽  
pp. 1583-1589 ◽  
Author(s):  
Raquel Barrio ◽  
Marta López-Capapé ◽  
Itziar Martinez-Badás ◽  
Angel Carrillo ◽  
Jose Moreno ◽  
...  
Keyword(s):  
Children And Adolescents ◽  
Term Treatment ◽  
Graves Disease ◽  
Long Term Treatment

Pharmacogenomics and Efficacy of Risperidone Long-term Treatment in Thai Autistic Children and Adolescence

2017 ◽  
Vol 41 (S1) ◽  
pp. S218-S219
Author(s):  
N. Nuntamool ◽  
N. Ngamsamut ◽  
N. Vanwong ◽  
A. Puangpetch ◽  
M. Chamnanphon ◽  
...  
Keyword(s):  
Autistic Disorder ◽  
Clinical Symptoms ◽  
Term Treatment ◽  
Small Sample ◽  
Autistic Children ◽  
Gene Variation ◽  
Long Term Treatment ◽  
Children And Adolescence ◽  
Symptom Group

Risperidone, atypical antipsychotics, was approved for irritability in autistic disorder. However, some patients had minimal improvement or no response to this treatment. The purpose of this study was to evaluate the association of pharmacogenomics factors and clinical outcomes in autistic children and adolescence who treated with risperidone for long periods. Sixty-seven autistic subjects diagnosed with DSM-IV criteria and treated with risperidone more than 1 year were evaluated clinical symptom by CGI, aggressive, over activity, and repetitive score. Polymorphisms of ABCB1, CYP2D6, DRD2, DRD3, and HTR2A were analyzed. Almost patients showed stable symptom on aggressive (91.04%), over activity (73.13%), repetitive (68.25%) behavior, and all clinical symptoms (82.09%). Only 4.48% of patients showed minimally worse on CGI-I score. Patients in non-stable of all symptom group had DRD2 Taq1A non-wildtype (TT and CT) frequencies higher than clinical stable group (P = 0.046), whereas other genes polymorphism showed no significant association. Interestingly, there was no patient with HTR2A-1438G > A wildtype in all non-stable symptoms. However, there was no significant association due to small sample sizes. Drug levels (RIS, 9OH-RIS, and active moiety) did not show the association with any clinical outcome. Increased appetite was the common ADRs, which associated with high body weight, whereas there was not significantly associated with genetic variations and non-genetic information. In conclusion, risperidone showed efficacy to control autism, especially aggressive symptom in long-term treatment. However, dopamine 2 gene variation affect to non-stable in risperidone treated patients. This study supports pharmacogenomics testing for personalized therapeutics of risperidone in autistic disorder.Disclosure of interestThe authors have not supplied their declaration of competing interest.

scholarly journals Long-term treatment outcomes of children and adolescents with lymphoblastic lymphoma treated with various regimens: a single-center analysis

2020 ◽  
Vol 55 (4) ◽  
pp. 262-274
Author(s):  
Ho Jung Choi ◽  
Juhee Shin ◽  
Sunghan Kang ◽  
Jin Kyung Suh ◽  
Hyery Kim ◽  
...  
Keyword(s):  
Children And Adolescents ◽  
Treatment Outcomes ◽  
Term Treatment ◽  
Lymphoblastic Lymphoma ◽  
Single Center ◽  
Long Term Treatment
Sign in / Sign up

Export Citation Format

Share Document